ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Two years on and confused w/last labs
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 156030" data-attributes="member: 13851"><p>Here is a 2017 study using TC sub-q.</p><p></p><p></p><p><strong>Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone </strong></p><p></p><p></p><p></p><p></p><p><strong>Purpose:</strong> Intramuscular (IM) testosterone is the most common modality for testosterone therapy of both male hypogonadism and female-to-male (FTM) gender transition. However, IM injections can be painful and often are not self-administered by the patient. The objective of this study was to further characterize subcutaneous (SC) administration of testosterone as an effective and safe alternative to IM injections by evaluating the pharmacodynamics of serum total and free testosterone concentrations between weekly testosterone injections.</p><p></p><p><strong>Methods:</strong> Eleven FTM transgender patients already receiving <span style="color: rgb(184, 49, 47)"><strong>weekly SC testosterone cypionate </strong></span>with documented therapeutic levels prior to enrollment had free and total serum testosterone levels measured at eight different time points during a 1-week dosing interval.</p><p></p><p><strong>Results:</strong> Mean levels of total and free testosterone were stable and remained well within the normal range between injections. Overall mean 6 standard deviation levels for the seven samples taken between injections were 627 ± 206 ng/dL (range, 205 to 1410) for total testosterone and 146 ± 51 pg/mL (range, 38 to 348) for free testosterone. No adverse effects were encountered.</p><p></p><p><strong>Conclusions:</strong> The results of this study support use of SC testosterone to achieve therapeutic and stable serum testosterone levels for the purpose of gender transition.<strong><span style="color: rgb(184, 49, 47)"> It is anticipated that these results can be extended to hypogonadal men. </span></strong>This route may be preferred over IM testosterone because it is relatively painless and easy to self-inject thus allowing for the convenience and economy of patient self administration.</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>Mean serum concentrations of total testosterone and free testosterone over 1 week are displayed for the 11 patients in Fig. 1(a) and 1(b), respectively. Mean serum total testosterone remained within the normal range throughout the 7-day interval between doses. There was a significant effect of time on serum total testosterone level (ptime = 0.006 by mixed models analysis) and on free testosterone level (ptime = 0.003 by mixed models analysis) during the 7 days between injections.</p><p></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>In post hoc analysis, paired comparisons between time points indicated no significant difference among serum total testosterone levels measured</strong></span><span style="color: rgb(44, 130, 201)"><strong> 6 hours to 5 days after injection;</strong></span><span style="color: rgb(184, 49, 47)"><strong> there was, however, a significant decrease at 7 days, compared both with the initial postinjection measurement (656 ± 244 ng/dL and 477 ± 185 ng/dL, P = 0.012) and the 5-day measurement (621 ± 321 ng/dL and 477 ± 185 ng/dL, P = 0.023).</strong></span><span style="color: rgb(44, 130, 201)"><strong> Compared with baseline preinjection values, serum concentrations increased significantly at 6 hours after injection for both total testosterone (497 ± 140 and 656 ± 244, P = 0.02) and free testosterone 118 ± 46 pg/mL and 151 ± 69 pg/mL, P = 0.003).</strong></span> There was no significant difference in serum levels between the two samples drawn 7 days apart immediately prior to testosterone injections for both total testosterone (497 ± 140 and 477 ± 185 ng/dL, P = 0.58) and free testosterone (118 ± 46 and 107 ± 49 pg/mL, P = 0.25). Individual total testosterone and free testosterone data are shown in Fig. 2(a) and 2(b), respectively. One patient (testosterone dose, 50 mg) had one total testosterone measurement below normal range (immediately prior to subsequent dose) and one patient (testosterone dose, 100 mg) had four measurements above normal range [Fig. 2(a)]. The rise in serum testosterone levels above the normal range was confirmed by duplicate serum testosterone measurements using the reserve samples. We confirmed with this patient and all others that they did not take any testosterone (injection or otherwise) in addition to the injections prescribed at 7-day intervals. All patients with serum testosterone levels within the lower half of the normal range were receiving a dose of 50 mg per week. The median (range) interindividual CV for serum total testosterone was 37.2% (25.6% to 51.7%) and the intraindividual CV was 20.2% (7.0% to 30.4%). There was a significant inverse relationship between intraindividual CV and body mass index (BMI; r 2 = 0.486, P = 0.017).</p><p></p><p></p><p></p><p></p><p>[ATTACH=full]8081[/ATTACH]</p><p><strong><span style="color: rgb(184, 49, 47)">Figure 1. </span>Serum total and free testosterone over a 1-week treatment cycle. Serum measurements taken at 0 and 7 days were from samples drawn immediately prior to SC testosterone injection. Dashed lines represent the lower and upper values of normal range for each total free testosterone. Data are shown as mean 6 standard deviation.</strong></p><p></p><p></p><p>Peak TT/FT levels 24 hrs.</p></blockquote><p></p>
[QUOTE="madman, post: 156030, member: 13851"] Here is a 2017 study using TC sub-q. [B]Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone [/B] [B]Purpose:[/B] Intramuscular (IM) testosterone is the most common modality for testosterone therapy of both male hypogonadism and female-to-male (FTM) gender transition. However, IM injections can be painful and often are not self-administered by the patient. The objective of this study was to further characterize subcutaneous (SC) administration of testosterone as an effective and safe alternative to IM injections by evaluating the pharmacodynamics of serum total and free testosterone concentrations between weekly testosterone injections. [B]Methods:[/B] Eleven FTM transgender patients already receiving [COLOR=rgb(184, 49, 47)][B]weekly SC testosterone cypionate [/B][/COLOR]with documented therapeutic levels prior to enrollment had free and total serum testosterone levels measured at eight different time points during a 1-week dosing interval. [B]Results:[/B] Mean levels of total and free testosterone were stable and remained well within the normal range between injections. Overall mean 6 standard deviation levels for the seven samples taken between injections were 627 ± 206 ng/dL (range, 205 to 1410) for total testosterone and 146 ± 51 pg/mL (range, 38 to 348) for free testosterone. No adverse effects were encountered. [B]Conclusions:[/B] The results of this study support use of SC testosterone to achieve therapeutic and stable serum testosterone levels for the purpose of gender transition.[B][COLOR=rgb(184, 49, 47)] It is anticipated that these results can be extended to hypogonadal men. [/COLOR][/B]This route may be preferred over IM testosterone because it is relatively painless and easy to self-inject thus allowing for the convenience and economy of patient self administration. Mean serum concentrations of total testosterone and free testosterone over 1 week are displayed for the 11 patients in Fig. 1(a) and 1(b), respectively. Mean serum total testosterone remained within the normal range throughout the 7-day interval between doses. There was a significant effect of time on serum total testosterone level (ptime = 0.006 by mixed models analysis) and on free testosterone level (ptime = 0.003 by mixed models analysis) during the 7 days between injections. [COLOR=rgb(184, 49, 47)][B]In post hoc analysis, paired comparisons between time points indicated no significant difference among serum total testosterone levels measured[/B][/COLOR][COLOR=rgb(44, 130, 201)][B] 6 hours to 5 days after injection;[/B][/COLOR][COLOR=rgb(184, 49, 47)][B] there was, however, a significant decrease at 7 days, compared both with the initial postinjection measurement (656 ± 244 ng/dL and 477 ± 185 ng/dL, P = 0.012) and the 5-day measurement (621 ± 321 ng/dL and 477 ± 185 ng/dL, P = 0.023).[/B][/COLOR][COLOR=rgb(44, 130, 201)][B] Compared with baseline preinjection values, serum concentrations increased significantly at 6 hours after injection for both total testosterone (497 ± 140 and 656 ± 244, P = 0.02) and free testosterone 118 ± 46 pg/mL and 151 ± 69 pg/mL, P = 0.003).[/B][/COLOR] There was no significant difference in serum levels between the two samples drawn 7 days apart immediately prior to testosterone injections for both total testosterone (497 ± 140 and 477 ± 185 ng/dL, P = 0.58) and free testosterone (118 ± 46 and 107 ± 49 pg/mL, P = 0.25). Individual total testosterone and free testosterone data are shown in Fig. 2(a) and 2(b), respectively. One patient (testosterone dose, 50 mg) had one total testosterone measurement below normal range (immediately prior to subsequent dose) and one patient (testosterone dose, 100 mg) had four measurements above normal range [Fig. 2(a)]. The rise in serum testosterone levels above the normal range was confirmed by duplicate serum testosterone measurements using the reserve samples. We confirmed with this patient and all others that they did not take any testosterone (injection or otherwise) in addition to the injections prescribed at 7-day intervals. All patients with serum testosterone levels within the lower half of the normal range were receiving a dose of 50 mg per week. The median (range) interindividual CV for serum total testosterone was 37.2% (25.6% to 51.7%) and the intraindividual CV was 20.2% (7.0% to 30.4%). There was a significant inverse relationship between intraindividual CV and body mass index (BMI; r 2 = 0.486, P = 0.017). [ATTACH=full]8081[/ATTACH] [B][COLOR=rgb(184, 49, 47)]Figure 1. [/COLOR]Serum total and free testosterone over a 1-week treatment cycle. Serum measurements taken at 0 and 7 days were from samples drawn immediately prior to SC testosterone injection. Dashed lines represent the lower and upper values of normal range for each total free testosterone. Data are shown as mean 6 standard deviation.[/B] Peak TT/FT levels 24 hrs. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Two years on and confused w/last labs
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top